ReviewJournal of hematology & oncology2022
Emerging role of RNA sensors in tumor microenvironment and immunotherapy.
Review in Journal of hematology & oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 24 citations in OpenAlex.
- FBXW5 blunts RIGI/MDA5/IFN signaling to drive immune evasion and chemo-immune resistance in triple-negative breast cancer models.The Journal of clinical investigation · 2026Article
- LINE-1 Epigenetic Repression and Regulation of Immunity.Viruses · 2026Review
- Article
- Pan-cancer analysis reveals context-dependent roles of LINE-1 ORF1p in immune regulation and copy number alterations.bioRxiv : the preprint server for biology · 2025Article
- Targeting pattern recognition receptors for cancer therapy: Mechanisms and strategies.Acta pharmaceutica Sinica. B · 2025Review
- Nanoparticle Delivery of Alu RNA Adjuvants Enhances Vaccine Immunogenicity.ACS applied materials & interfaces · 2025Article
- Targeting PGK1: A New Frontier in Breast Cancer Therapy Under Hypoxic Conditions.Current issues in molecular biology · 2024Review
- Innate immune responses to RNA: sensing and signaling.Frontiers in immunology · 2024Review
- 6-O-endosulfatases in tumor metastasis: heparan sulfate proteoglycans modification and potential therapeutic targets.American journal of cancer research · 2024Review
- Emerging prospects of mRNA cancer vaccines: mechanisms, formulations, and challenges in cancer immunotherapy.Frontiers in immunology · 2024Review
- Understanding nucleic acid sensing and its therapeutic applications.Experimental & molecular medicine · 2023Review
- Cellular Stress: Modulator of Regulated Cell Death.Biology · 2023Review
- Exosomes-mediated crosstalk between glioma and immune cells in the tumor microenvironment.CNS neuroscience & therapeutics · 2023Review
- Exploiting RIG-I-like receptor pathway for cancer immunotherapy.Journal of hematology & oncology · 2023Review
- Damage-mediated macrophage polarization in sterile inflammation.Frontiers in immunology · 2023Review
- Immune responses elicited by ssRNA(-) oncolytic viruses in the host and in the tumor microenvironment.Journal of cancer metastasis and treatment · 2023Article
- Emerging Progress of RNA-Based Antitumor Therapeutics.International journal of biological sciences · 2023Review
- JMJD4-demethylated RIG-I prevents hepatic steatosis and carcinogenesis.Journal of hematology & oncology · 2022Article
- The intersection molecule MDA5 in Cancer and COVID-19.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
RNA sensors detect foreign and endogenous RNAs to protect the host by initiating innate and adaptive immune response. In tumor microenvironment (TME), activation of RNA sensors induces tumor-inhibitory cytotoxic T lymphocyte responses and inhibits the activity of immunosuppressive cells though stimulating type I IFN signaling pathway. These characteristics allow RNA sensors to be prospective targets in tumor immunotherapy. Therefore, a comprehensive understanding of the roles of RNA sensors in TME could provide new insight into the antitumor immunotherapy. Moreover, RNA sensors could be prominent triggering targets to synergize with immunotherapies. In this review, we highlight the diverse mechanisms of RNA sensors in cancer immunity and their emerging contributions in cancer immunotherapy, including monotherapy with RNA sensor agonists, as well as combination with chemotherapy, radiotherapy, immune checkpoint blockade or cancer vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.